Trials / Active Not Recruiting
Active Not RecruitingNCT03409016
Biomarkers of Immune-Related Toxicity
Identifying Biomarkers of Immune-Related Toxicity in Cancer Patients Treated With Immune Checkpoint Inhibitors; A Pilot Project
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 69 (estimated)
- Sponsor
- University of Colorado, Denver · Academic / Other
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-center, correlative pilot study evaluating potential biomarkers predictive of immune-related adverse events associated with immune checkpoint inhibitor therapy.
Detailed description
This is a single-center, correlative pilot study evaluating potential biomarkers predictive of immune-related adverse events associated with immune checkpoint inhibitor therapy. The study includes a control population of patients receiving standard chemotherapy as a comparator. Patients will undergo blood draws at 4 time-points while on standard of care treatment. There are no study-related medications or interventions beyond blood sampling.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Blood Testing | Patients will undergo therapy per standard protocol. There are no study-related medications or interventions beyond blood testing. |
Timeline
- Start date
- 2018-04-18
- Primary completion
- 2025-05-28
- Completion
- 2026-05-28
- First posted
- 2018-01-24
- Last updated
- 2025-09-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03409016. Inclusion in this directory is not an endorsement.